Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S331000
Reexamination Certificate
active
07087618
ABSTRACT:
The present invention provides compounds of formula (I):wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents
REFERENCES:
patent: 4576952 (1986-03-01), Hurst et al.
patent: 4621089 (1986-11-01), Ward et al.
patent: 4670432 (1987-06-01), Ward et al.
patent: 4985444 (1991-01-01), Shiokawa et al.
patent: 5155114 (1992-10-01), Shiokawa et al.
patent: 5204346 (1993-04-01), Shiokawa et al.
patent: 5234930 (1993-08-01), Shiokawa et al.
patent: 5296490 (1994-03-01), Shiokawa et al.
patent: 5300478 (1994-04-01), Michaely et al.
patent: 5498774 (1996-03-01), Mitsudera et al.
patent: 5552422 (1996-09-01), Gauthier et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5773530 (1998-06-01), Akahane et al.
patent: 5990148 (1999-11-01), Isakson et al.
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6207675 (2001-03-01), Carry et al.
patent: 6919352 (2005-07-01), Chamberlain et al.
patent: 2004/0053942 (2004-03-01), Alberti et al.
patent: 0 404 190 (1990-06-01), None
patent: 0 404 190 (1990-06-01), None
patent: 0 379 979 (1990-08-01), None
patent: 0 467 248 (1991-07-01), None
patent: 0 497 258 (1992-01-01), None
patent: 2 757 059 (1998-06-01), None
patent: 0 364 204 (1989-10-01), None
patent: WO 91 00092 (1991-01-01), None
patent: WO 91 19497 (1991-12-01), None
patent: WO 95 00501 (1995-01-01), None
patent: WO 96 06840 (1996-03-01), None
patent: WO 96 21667 (1996-07-01), None
patent: WO 96 31509 (1996-10-01), None
patent: WO 96 41625 (1996-12-01), None
patent: WO 96 41626 (1996-12-01), None
patent: WO 96 41645 (1996-12-01), None
patent: WO 98/56377 (1998-12-01), None
patent: WO 99 12930 (1999-03-01), None
patent: WO 99/58523 (1999-11-01), None
patent: WO 99/59585 (1999-11-01), None
patent: WO 99/64419 (1999-12-01), None
patent: WO 00/26216 (2000-05-01), None
patent: WO 00/52008 (2000-09-01), None
patent: WO 01/00615 (2001-01-01), None
patent: WO 01 14375 (2001-03-01), None
patent: WO 02/16359 (2002-02-01), None
patent: WO 02 18382 (2002-03-01), None
patent: WO 02 48147 (2002-06-01), None
patent: WO 02/048148 (2002-06-01), None
patent: WO 02 066481 (2002-08-01), None
patent: WO 03/00682 (2003-01-01), None
Vane, J. et al. “Towards a Better Aspirin,” Nature, vol. 367, Jan. 20, 1994, pp. 215-216.
Carter, J. et al. “Recently Reported Inhibitors of Cyclooxygenase-2.” Exp. Opin. Ther. Patents (1998), 8(1), pp. 21-29.
Talley, JJ., “Review, Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Selective Inhibitors of Cyclooxygenase-2.” Exp. Opin. Ther. Patents (1997) 7(1), pp. 55-62.
Roy, P., “A New Series of Selective Cox-2 Inhibitors: 5,6-Diarylthiazolo [3,2-b][1,22,4] Triazoles,”Bioorganiz&Med. Chem. Ltrs., vol. 7, No. 1, 1997, pp. 57-62.
Therien, Michael, Synthesis and Biological Evaluation of 5, 6-Diarylimidazo[2.1-b]Thiazole As Selective Cox-2 Inhibitors,Bioorganic&Med. Chem. Ltrs., vol. 7, No. 1, 1997, pp. 47-52.
Akahane, Atsushi, “Discovery of 6-Oxo-3-(2-Phenlypyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic Acid (FR 838): A Novel Xanthine Adenosine A1Receptor Antagonist with Potent Diuretic Activity,”Journal of Medicinal Chemistry, vol. 42, No. 5, 1999, pp. 779-783.
Talley, John J., 5 Selective Inhibitors of Cyclooxygenase-2 (COX-2)Progress in Medicinal Chemistry, vol. 36, (1999): pp. 201-234.
Boehm, J.C., et al. “1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency.” J. Med. Chem. 1996, 39, pp. 3929-3937.
Hanson, G.J., et al. “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p. 38 kinase.” Expert Opinion Ther. Patents, 1997, 7(7):729-733.
Roizman, B., et al. “The Family Herpesviridae: A Brief Introduction.” Fields Virology, vol. 2, 4thEdition, pp. 2381-2397, 2001.
Douglas, R.G., Jr. “Introduction to Viral Diseases.” Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Bosseray, A., et al. “What's New in Vaccines Against Herpes Simplex Infections.” PubMed Abstract. Pathol. Biol. 50(8): 483-92, Oct. 2002.
Razonable, R., et al. “Herpesvirus Infections in Transplant Recipients: Current Challenges in the Clinical Management of Cytomegalovirus and Epstein-Barr Virus Infection.” PubMed Abstract. Herpes 10(3):60-5, Dec. 2003.
Chamberlain Stanley D.
Gudmundsson Kristjan
Johns Brian A.
Morgan Lovie Ann
Rao Deepak
SmithKline Beecham Corporation
LandOfFree
Pyrazolopyridinyl pyrimidine therapeutic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridinyl pyrimidine therapeutic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridinyl pyrimidine therapeutic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3668421